trending Market Intelligence /marketintelligence/en/news-insights/trending/4ujwa9hfovgdl7hcodwmsg2 content esgSubNav
In This List

Chengdu Rongsheng Pharmaceutical to acquire stake in Sinopharm Group unit

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Chengdu Rongsheng Pharmaceutical to acquire stake in Sinopharm Group unit

Chengdu Rongsheng Pharmaceutical Co. Ltd. has reached an agreement with Sinopharm Group Guangdong Medi-World Pharmaceutical Co. to acquire a remaining 20% equity interest in Sinopharm Group Guizhou Blood Products Co. Ltd. for HK$102.4 million.

Chengdu Rongsheng Pharmaceutical is an indirect subsidiary of China National Pharmaceutical Group Corp., which is also the holding company of Sinopharm Hong Kong and related units. Chengdu Rongsheng Pharmaceutical develops protein-based therapies in the areas of immunotherapy and critical care.

Sinopharm Group Guangdong Medi-World Pharmaceutical acquired a 51% equity interest in Sinopharm Group Guizhou Blood in January 2013, later selling 31% of its stake for about HK$157.6 million. Sinopharm Group Guizhou Blood develops and sells plasma-based biopharmaceutical products in China.

The deal is expected to close by year-end subject to required approvals.